Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REXALL SUNDOWN FORMS OTC/PRIVATE-LABEL SALES DIVISION TO TARGET MANAGED-CARE

This article was originally published in The Tan Sheet

Executive Summary

REXALL SUNDOWN FORMS OTC/PRIVATE-LABEL SALES DIVISION TO TARGET MANAGED-CARE and institutional providers such as hospitals, nursing homes and mail-order pharmacies, the company announced Nov. 11. The new Pharmaceutical and Health Services division, which is based at Rexall's headquarters in Fort Lauderdale, Fla., commenced operations Nov. 8. Although staffing is not complete, the division is eventually expected to operate with a sales force of five people. Rexall said it expects the new marketing segment to provide its subsidiary, Pennex Laboratories, with an "opportunity to expand its business, not only with over-the-counter pharmaceutical products, but with other products as prospects become available." Rexall did not rule out the possibility in the future of marketing prescription generic drugs developed and manufactured at Pennex through the new sales division. The division will be led by former board member John lsakson, who assumes the title of VP-sales and marketing/pharmaceutical and health care. Rexall Sundown VP Armend Szmulewitz will assume responsibilities for product development and administration. In accepting the new appointment, Isakson has resigned as director of Rexall. Isakson has been president of MDS Group, a marketing and consulting firm for manufacturers since October 1992. Previously, he was VP-sales for Baker Cummins Pharmaceuticals. Prior to that, Isakson was director of sales at R. P. Scherer, North America. He also served in various capacities at Wallace Labs. Szmulewitz joined Rexall Sundown in July 1987 and has been CEO of the company's Rexall division since that time. In March, he also assumed the title of VP-research and product development. The new division will be based in Boca Raton, Fla., where Rexall Sundown is relocating its headquarters on Dec. 17. The company is currently constructing its first vitamin manufacturing plant in Boca Raton. The facility is scheduled to initiate operations by April 1994. With the additions of both a pharmaceutical and a vitamin plant, Rexall is moving away from its dependence on contract manufacturers. Rexall acquired Verona, Penn.-based Pennex Labs in September ("The Tan Sheet" Aug. 16, p. 19), and is using proceeds from its June IPO to fund its manufacturing strategy ("The Tan Sheet" May 3, p. 4).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082149

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel